Showing results (1-10 of 346) with videos related to
Sort By:
Pageof 35
Current Opinion in Neurology|May 14, 2005
Current trials in multiple sclerosis: established evidence and future hopesJoep Killestein, Chris H PolmanNature Reviews. Neurology|March 3, 2011
Determinants of interferon β efficacy in patients with multiple sclerosisJoep Killestein, Chris H PolmanThe Lancet. Neurology|October 22, 2011
Oral treatment for multiple sclerosisJoep Killestein, Richard A Rudick, Chris H PolmanJournal of the Neurological Sciences|June 14, 2005
Glutamate inhibition in MS: the neuroprotective properties of riluzoleJoep Killestein, Nynke F Kalkers, Chris H PolmanDrugs|January 16, 2004
Cannabinoids in multiple sclerosis: do they have a therapeutic role?Joep Killestein, Bernard M J Uitdehaag, Chris H PolmanMultiple Sclerosis (Houndmills, Basingstoke, England)|December 21, 2011
Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stoppedTheo Rispens, Anke Vennegoor, Gert Jan Wolbink, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|February 10, 2015
Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathyAnke Vennegoor, Johannis A van Rossum, Chris H Polman, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|July 6, 2013
Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patientsJohannis A van Rossum, Anke Vennegoor, Lisanne Balk, et al.Annals of Neurology|July 28, 2010
Natalizumab drug holiday in multiple sclerosis: poorly toleratedJoep Killestein, Anke Vennegoor, Eva M Strijbis, et al.Archives of Neurology|February 10, 2010
Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosisLaura F van der Voort, Francesca Gilli, Antonio Bertolotto, et al.Pageof 35